ReviewFrontiers in bioengineering and biotechnology2016
Lost in Translation: The Gap in Scientific Advancements and Clinical Application.
Review in Frontiers in bioengineering and biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- From bone replacement to regeneration. A biomaterials started journey.Materials today. Bio · 2026Review
- Recent advances in lipid nanoparticles for cancer vaccine delivery: Challenges and future perspectives.International journal of pharmaceutics: X · 2026Review
- Driving innovation in cancer symptom science through translational research: bridging science and practice.Current opinion in supportive and palliative care · 2026Review
- Tissue and organ engineering: Investor sentiments and analysis.Regenerative therapy · 2026Article
- Technologies to investigate the mechanisms of force-based manipulations: a narrative methods review.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- Trypanosomatid parasites, translational research in a One Health, One World environment.Frontiers in chemistry · 2026Review
- Novel Mixed Cancer-Cell Models Designed to Capture Inter-Patient Tumor Heterogeneity for Accurate Evaluation of Drug Combinations.International journal of molecular sciences · 2025Article
- Translational medicine: An effective approach to improve healthcare by research and innovation in developing countries.Medicine · 2025Review
- Advancing ADMET prediction through multiscale fragment-aware pretraining with MSformer-ADMET.Briefings in bioinformatics · 2025Article
- Genotype-Based Housing as a Potential Confounder in Studies Using Transgenic Mouse Models-Insight from the A53T Mouse Model of Parkinson's Disease.Biomedicines · 2025Article
- Supporting translation with early health technology assessment: from definition to action.International journal of technology assessment in health care · 2025Article
- Collecting Real-Life Psychophysiological Data via Wearables to Better Understand Child Behavior in a Children's Psychiatric Center: Mixed Methods Study on Feasibility and Implementation.JMIR formative research · 2025Article
- Article
- Lost in translation: the lack of agreement between surgeons and scientists regarding biomaterials research and innovation for treating bone defects.BMC medicine · 2024Article
- International online mentorship for translational researchers.BMC medical education · 2024Article
- How pharma can amplify product value with implementation science.Journal of comparative effectiveness research · 2024Article
- Deep-PK: deep learning for small molecule pharmacokinetic and toxicity prediction.Nucleic acids research · 2024Article
- Accumulation of liposomes in metastatic tumor sites is not necessary for anti-cancer drug efficacy.Journal of translational medicine · 2024Article
- Return on investment in science: twenty years of European Commission funded research in Alzheimer's dementia, breast cancer and prostate cancer.Cost effectiveness and resource allocation : C/E · 2024Article
- A novel preclinical model of the normal human breast.Journal of mammary gland biology and neoplasia · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The evolution of medicine and medical technology hinges on the successful translation of basic science research from the bench to clinical implementation at the bedside. Out of the increasing need to facilitate the transfer of scientific knowledge to patients, translational research has emerged. Significant leaps in improving global health, such as antibiotics, vaccinations, and cancer therapies, have all seen successes under this paradigm, yet today, it has become increasingly difficult to realize this ideal scenario. As hospital revenue demand increases, and financial support declines, clinician-protected research time has been limited. Researchers, likewise, have been forced to abandon time- and resource-consuming translational research to focus on publication-generating work to maintain funding and professional advancement. Compared to the surge in scientific innovation and new fields of science, realization of transformational scientific findings in device development and materials sciences has significantly lagged behind. Herein, we describe: how the current scientific paradigm struggles in the new health-care landscape; the obstacles met by translational researchers; and solutions, both public and private, to overcoming those obstacles. We must rethink the old dogma of academia and reinvent the traditional pathways of research in order to truly impact the health-care arena and ultimately those that matter most: the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.